[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
In March 2022, [<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other thera...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2022-10-01
|
| Serie: | Pharmaceuticals |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/1424-8247/15/10/1292 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|